GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Forward PE Ratio

AEterna Zentaris (STU:ET80) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Forward PE Ratio?

AEterna Zentaris's Forward PE Ratio for today is 0.00.

AEterna Zentaris's PE Ratio without NRI for today is 0.00.

AEterna Zentaris's PE Ratio for today is 0.00.


AEterna Zentaris Forward PE Ratio Historical Data

The historical data trend for AEterna Zentaris's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Forward PE Ratio Chart

AEterna Zentaris Annual Data
Trend
Forward PE Ratio

AEterna Zentaris Quarterly Data
Forward PE Ratio

Competitive Comparison of AEterna Zentaris's Forward PE Ratio

For the Biotechnology subindustry, AEterna Zentaris's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Forward PE Ratio falls into.



AEterna Zentaris Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


AEterna Zentaris  (STU:ET80) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


AEterna Zentaris Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (STU:ET80) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines